Insulin — Degludec — Half-Life, Dosing & Protocol Guide

Also known as: Tresiba, ultra-long-acting insulin

Pharmacokinetics & Mechanism

Insulin degludec (Tresiba) has a steady-state terminal half-life of approximately 25 hours, independent of dose, per the FDA Tresiba prescribing label (NDA 203314). A hexadecanedioyl fatty diacid at B29Lys enables multi-hexamer chain formation in subcutaneous tissue → slow dissociation → albumin binding → ultra-long duration exceeding 42 hours. The flat, stable concentration profile provides the lowest fasting blood glucose variability of any available basal insulin. Flexible dosing: injection time can vary by ±8 hours from planned time without affecting glycaemic control per the FDA label.

Track Insulin — Degludec in Halflife

The Halflife app models your Insulin — Degludec concentration curve in real time — see exactly when your dose peaks, when it troughs, and how it overlaps with other compounds in your stack. All stored on-device, no account required.